Benitec Biopharma Inc. announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program.
[Benitech Biopharma, Inc.]
Home Newsletters Muscle Cell News Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program
